Clinical Trial Update: MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MABp1 for hidradenitis suppurativa in patients refractory to adalimumab has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• MABp1

Snippet

Sponsor: Evangelos J. Giamarellos-Bourboulis, M.D. | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: COMPLETED